This week, a court ordered a Medtronic whistleblower to hand over records of his media contacts; Cue Health was awarded $28m to develop a multi-disease respiratory panel; and the FDA granted a zero fluoroscopy Indication to some Biosense Webster cardiac ablation devices.

On 19 July, Biosense Webster announced the final enrollment in the SmartfIRE trial of its Thermocool Smarttouch SF cardiac ablation catheter with the Trupulse generator and Carto imaging system.

In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical, a Marseille-based company applying artificial intelligence to electrophysiology. Volta has raised over €70m and is sponsoring the TAILORED AF trial to show that its software can make atrial fibrillation ablation more effective.

Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.